LncRNA NNT-AS1 contributes to the cisplatin resistance of cervical cancer through NNT-AS1/miR-186/HMGB1 axis

BACKGROUND: Cisplatin (DDP) is a major chemotherapeutic drug which was widely used for cervical cancer (CC) patients with advanced or recurrent although its limitation in the development of resistance. LncRNA nicotinamide nucleotide transhydrogenase-antisense RNA1 (NNT-AS1) has been reported to be i...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yanjie, Guo, Ruixia, Qiao, Yuhuan, Han, Liping, Liu, Mingzhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247171/
https://www.ncbi.nlm.nih.gov/pubmed/32489326
http://dx.doi.org/10.1186/s12935-020-01278-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247171/
https://www.ncbi.nlm.nih.gov/pubmed/32489326
http://dx.doi.org/10.1186/s12935-020-01278-9

Ejemplares similares